1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,276 | 1,320 | 22:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| Mi | BIOCYTOGEN-B (02315): NOTICE OF THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| Mi | BIOCYTOGEN-B (02315): CIRCULAR FOR THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| Mi | BIOCYTOGEN-B (02315): 2024 ANNUAL REPORT | 2 | HKEx | ||
| 26.03. | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
| 14.03. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 4 | HKEx | ||
| 28.02. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT THE DEEPSEEK PLATFORM LOCALIZED DEPLOYMENT AND UPGRADE IN RESEARCH AND DEVELOPMENT STRATEGY OF ANTIBODY DRUGS ... | 1 | HKEx | ||
| 21.02. | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR ENDED DECEMBER 31, 2024 | 1 | HKEx | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.01. | BIOCYTOGEN-B (02315): POSITIVE PROFIT ALERT | 2 | HKEx | ||
| 09.01. | Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment | 294 | Business Wire | Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech, a... ► Artikel lesen | |
| 09.01. | SOTIO Biotech: SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target | 321 | Business Wire | SOT109 will leverage antibodies generated with Biocytogen's proprietary RenMab platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers SOTIO Biotech, a clinical-stage... ► Artikel lesen | |
| 08.01. | Biocytogen und Acepodia bündeln ihre Kräfte, um bispezifische Antikörper und Dual-Payload-ADCs zur Behandlung komplexer Tumore voranzutreiben | 315 | Business Wire | Zusammenarbeit initiiert Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten mit doppelter Nutzlast (BsAD2Cs)
Biocytogens RenLite® trifft auf Acepodias AD2C für präzise onkologische... ► Artikel lesen | |
| 07.01. | Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors | 418 | Business Wire | Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs)
Biocytogen's RenLite® meets Acepodia's AD2C for precision oncology solutions
Biocytogen... ► Artikel lesen | |
| 06.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT SHARE PURCHASE BY TRUSTEE PURSUANT TO SHARE AWARD SCHEME | 2 | HKEx | ||
| 18.12.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen gibt bekannt, dass Adcendo ApS die Antikörperoption ausübt, um die ADC-Entwicklung zu beschleunigen | 399 | Business Wire | Adcendo übt seine Option aus, die vollständig humanen Antikörper von Biocytogen zu nutzen, um seine ADC-Pipeline für Krebserkrankungen mit hohem ungedecktem medizinischen Bedarf weiter auszubauen... ► Artikel lesen | |
| 16.12.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development | 305 | Business Wire | Adcendo exercises its option to utilize Biocytogen's fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need
This collaboration further validates... ► Artikel lesen | |
| 11.11.24 | Ideaya pushes ahead with Biocytogen bispecific ADC bet | 2 | FierceBiotech | ||
| 11.11.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | 432 | Business Wire | IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen's potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034)... ► Artikel lesen | |
| 11.11.24 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT IDEAYA'S NOMINATION OF DEVELOPMENT CANDIDATE IDE034, A POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 3 | HKEx | ||
| 31.07.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program | 366 | Business Wire | Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program
B7H3/PTK7... ► Artikel lesen |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,150 | -15,49 % | PTA-AFR: Medigene AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Medigene AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Medigene AG: Vorabbekanntmachung... ► Artikel lesen | |
| BIOFRONTERA | 2,310 | -4,55 % | EQS-HV: Biofrontera AG: Bekanntmachung der Einberufung zur Hauptversammlung am 28.05.2025 in Köln mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Biofrontera AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
Biofrontera AG: Bekanntmachung der Einberufung zur Hauptversammlung am 28.05.2025 in Köln mit dem... ► Artikel lesen | |
| CLINUVEL | 6,210 | +0,81 % | Clinuvel Pharmaceuticals Aktie: Faktoren für Kursbewegungen | Trotz rückläufiger Kurse halten Analysten an Kaufempfehlungen für Clinuvel fest. Das durchschnittliche Kursziel liegt deutlich über dem aktuellen Stand. Die Clinuvel-Aktie zeigt heute eine leichte Erholung... ► Artikel lesen | |
| EDITAS MEDICINE | 1,302 | -4,16 % | Editas Medicine, Inc.: Editas Medicine Announces Chief Financial Officer Transition | Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.... ► Artikel lesen | |
| BLUEBIRD BIO | 3,660 | +1,67 % | Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline | ||
| CELLECTAR BIOSCIENCES | 0,270 | -1,46 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
| ASEP MEDICAL | 0,400 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 17.04.2025 | The following instruments on XETRA do have their first trading 17.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 17.04.2025
Aktien
1 AU0000082422 Harvest Technology Group... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,560 | -0,97 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of... ► Artikel lesen | |
| CLEAN HARBORS | 182,10 | -1,59 % | Truist cuts Clean Harbors stock price target to $250 | ||
| SPERO THERAPEUTICS | 0,626 | -1,26 % | The Spero Clinic: When a Simple Ankle Injury Turns Into CRPS: Moana Ruhfass's Journey | FAYETTEVILLE, ARKANSAS / ACCESS Newswire / April 8, 2025 / While, for most children, life is an adventure and a never-ending road of discovery, many others are not that lucky, facing a journey of pain... ► Artikel lesen | |
| MESOBLAST | 0,980 | +4,81 % | Mesoblast Limited: Mesoblast Extends Payer Coverage For Ryoncil to Over 100 Million US Lives | NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,330 | 0,00 % | CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress | Financial Performance: Strong Year-over-Year Improvement- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.- ... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,640 | +0,76 % | Protalix BioTherapeutics, Inc. - 8-K, Current Report | ||
| PALVELLA THERAPEUTICS | 23,400 | +5,41 % | Palvella Therapeutics Inc.: Palvella Therapeutics Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations | Fifth issued patent in the U.S. for QTORIN rapamycin with anticipated patent life extending into 2038 QTORIN rapamycin has the potential to be the first approved therapy and standard of care for microcystic... ► Artikel lesen | |
| MERSANA THERAPEUTICS | 0,347 | +1,70 % | Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,270 Euro und damit +0,16 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.
